Literature DB >> 990684

The response of lymph node metastases of testicular teratoma to radiation therapy.

C J Tyrrell, M J Peckham.   

Abstract

The response to radiation therapy of lymph nodes metastases from testicular teratomas has been examined in 117 Stage I and II patients treated between 1962 and 1972. It is not possible to obtain reliable estimates of the percentage Stage I patients with occult retroperitoneal node metastases; however, available evidence suggests that spread of tumour to the lymph nodes has occurred in a proportion (possibly as many as 50%) of patients in this category. Radiation therapy is an effective method of achieving tumour eradication and overall survival results in this group are good (84%). In a smaller group of Stage II patients with unequivocal lymphographic evidence of nodal spread, the effectiveness of irradiation is dependent upon tumour volume. In those patients with metastases 2 centimetres or less in diameter, the results of treatment are similar to Stage I and we have designated this group Stage IIa. In those patients with larger volume metastases, two thirds have developed abdominal node relapse, in most cases associated with distant spread. We have designated this group Stage IIb. The implications of these observations for overall management are discussed.

Entities:  

Mesh:

Year:  1976        PMID: 990684     DOI: 10.1111/j.1464-410x.1976.tb06654.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  6 in total

1.  Chemotherapy of disseminated testicular cancer.

Authors:  L H Einhorn; S D Williams
Journal:  West J Med       Date:  1979-07

Review 2.  Computed tomography in testicular disease: a review.

Authors:  J E Husband; J S Macdonald; M J Peckham
Journal:  J R Soc Med       Date:  1981-06       Impact factor: 5.344

3.  Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy.

Authors:  Shilajit D Kundu; Brett S Carver; Joel Sheinfeld
Journal:  Urology       Date:  2011-07-22       Impact factor: 2.649

Review 4.  Stage I nonseminomatous germ-cell testicular cancer--management options and risk-benefit considerations.

Authors:  J P Donohue; J A Thornhill; R S Foster; R G Rowland; R Bihrle
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

5.  Multiple secondary malignancies following radiation therapy for testicular cancer.

Authors:  Sam Neufeld; Tadeusz Kroczak; Darrel Drachenberg
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

6.  Lymphography in tumours of the urogenital tract.

Authors:  J Nuttall; J S Macdonald
Journal:  J R Soc Med       Date:  1978-01       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.